NCEL
NewcelX Ltd.
NASDAQ: NCEL · HEALTHCARE · BIOTECHNOLOGY
$3.42
+2.09% today
Updated 2026-04-29
Market cap
$17.27M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-6.93
Dividend yield
—
52W range
$2 – $31
Volume
0.0M
NewcelX Ltd. (NCEL) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | $10050.00 | $11408.00 | $11408.00 | $3321.00 |
| Gross profit | — | — | — | — | $-10050.00 | $-11408.00 | $-11408.00 | $-3321.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $4.32M | $708.00 | $1.70M | $99580.00 | $5.92M | $8.98M | $5.91M | $422051.00 |
| SG&A | $1.44M | $2740.00 | $3.30M | $2199.00 | $5941.00 | $6505.00 | $5.90M | $3.21M |
| Operating income | $-5.77M | $-3448.00 | $-4.20M | $-2.30M | $-11.86M | $-15.48M | $-11.81M | $-4.38M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-5.77M | — | $-430400.00 | $-2.63M | $-11.85M | $-15.47M | $-11.80M | $-3.63M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-11.53M | — | $-4.63M | — | $-11.86M | $-15.48M | $-11.81M | $-3.64M |
| Interest expense | $890403.00 | $1084.00 | $819711.00 | $233700.00 | $68134.00 | $100866.00 | $145153.00 | $150017.00 |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-6.66M | $-5146.00 | $-5.45M | $-2.86M | $-11.95M | $-16.50M | $-12.17M | $-1.98M |
| Net income growth (YoY) | — | +99.9% | -105752.0% | +47.5% | -317.5% | -38.1% | +26.2% | +83.7% |
| Profit margin | — | — | — | — | — | — | — | — |